We just released Volume 3 of our print magazine, ENMEDIA. Read our story on the BIOSECURE Act at the link below. #Biotech #Biopharma #HealthcarePolicy https://lnkd.in/gEw7hGde
ENTENTE Network
公共关系和沟通服务
ENTENTE Network of Companies: activations, branding, integrated reputation communications, engagement, behavior change
关于我们
ENTENTE Network of Companies encompasses publishing and corporate communications services. We champion innovation-driven organizations in pharma and life sciences, diagnostics, health delivery including digital health and hospital systems, food science, sustainable energy, and social impact.
- 网站
-
https://ententenetwork.com
ENTENTE Network的外部链接
- 所属行业
- 公共关系和沟通服务
- 规模
- 11-50 人
- 总部
- NYC Chicago London Dallas Madison Denver Florida
- 类型
- 私人持股
- 创立
- 2017
- 领域
- executive communications、branding、reputation、public affairs、strategy、consulting、innovation、activation、behavior change、patient engagement、disease awareness、integrated communication、publishing和media
地点
ENTENTE Network员工
-
Julian Leuthold
Founder & CEO at GetGlobal: Thrive in Foreign Markets
-
Jeremy Tunis
"Urgent Care" for Public Affairs, PR, Media, Policy. Deep experience with BH/acute hospitals, MedTech, other scrutinized sectors. Jewish nonprofit…
-
Virginia Amann
Strategic and Marketing Communications Leader. Science. Innovation. Founder/CEO/Shareholder ENTENTE Network of Companies
-
Devin Osting
Interim Executive Director of the Alliance for Aviation Across America
动态
-
Great story in Endpoints News by NewBiologix Igor Fisch on innovation in gene therapy production and why it matters for patient access of this life changing tech. #genetherapy
The high cost of #GeneTherapies, which can reach more than $4 million per dose, highlights the need for manufacturing solutions that can deliver these life-saving treatments to patients more affordably and at scale. At NewBiologix, we're leading the way with our Xcell? Portfolio, a suite of technologies to streamline rAAV production, improve yield consistency and lower costs. Our CEO, Igor Fisch, Ph.D., discusses these challenges and our innovative solutions in a recent article featured in Endpoints News. By developing stable cell lines to replace transient transfection methods, we’re tackling cost, scalability, and regulatory hurdles, making gene therapies more accessible. Read more: https://lnkd.in/edjeqEK4. #NewBiologix
Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks
endpts.com
-
It always feels a little like Christmas morning when we open up a box of fresh ENTENTE Network ENMEDIA Magazines. Excited to share Vol. 3 at the #BioFuture2024 conference this week hosted by Demy-Colton! If this year's BioFuture is anything to go by, the #biotech and #pharma industries are in for an exciting 2025. Looking forward to learning more about emerging technologies and #therapeutics and hope to find some new companies to include in Vol. 4 of our magazine. Please reach out if you would like to be featured! You can read the full version of our magazine here: https://bit.ly/3Aisa4u
-
Fabulous to see our colleague Jeremy Tunis included in Allison Carter's fabulous piece on best writing tips at PR Daily: "Brevity wins every friggin time. Adverbs and passive voice are writing killers if you want people to actually absorb your content." ????
I was blown away by the response to my post asking for communicators' best writing tips -- nearly 300 awesome insights. Here are just a handful of the best.
Communicators share their best writing tips - PR Daily
https://www.prdaily.com
-
?? The BioSecure Act: Balancing Security and Innovation in Biotechnology Join us on Monday, October 28, at 11:30 AM ET for an important discussion on The BioSecure Act, a landmark piece of legislation poised to shape the future of biotechnology. This panel, moderated by Virginia Amann, Founder of ENTENTE Network, will explore how The BioSecure Act, if passed by the Senate, could influence national security, ethics, and the potential for innovation in biotech, manufacturing, and #pharmaceutical industries. Industry leaders will dive into the intersection of #security and #innovation, providing key insights for the future of these fields. Panelists include:? ?? Max Bayer, Pharma Reporter, Endpoints News? ?? Seth Flaum, Partner, Wilson Sonsini Goodrich & Rosati? ?? Greg Simon, President, Simonovation, LLC? ?? Arda Ural, MSc, MBA, PhD, Americas Life Sciences Leader, EY ? ?? Register now: https://lnkd.in/e6iHWsFT ? ??? View the full agenda: https://lnkd.in/eg_j973P? ? This panel is part of a dynamic series of dialogues, panels, and fireside chats at #BioFuture2024, happening October 28-30 at Cure. in #NYC. Connect with global leaders, innovators, and investors as they tackle the most pressing issues in biotechnology and healthcare. ?? Partnering is now open—register and schedule one-to-one meetings in advance to connect with global industry leaders. ?? Learn more about BioFuture here: https://lnkd.in/eUurATbr ? ? #Biotech #BiotechLeaders #Innovation #BioSecure #FutureofHealthcare #HealthcareInnovation #BioFuture #DemyColton?
-
-
#ENTENTE congratulates Katherine J. Wu, PhD on receiving the inaugural Kovler Prize for Trust in Life Science Journalism from the Foundation for the National Institutes of Health (FNIH). This recognition highlights the role of trust in communicating scientific breakthroughs, especially at a time when public confidence in science has been deeply challenged. We believe that #trust is essential for effective #sciencecommunication. It's not only about conveying facts–it's also about creating credibility and transparency.
The FNIH Awards the Inaugural Kovler Prize for Trust in Life Science Journalism to Katherine J. Wu, PhD | FNIH
https://fnih.org
-
Join our CEO Virginia Amann and an esteemed panel at BioFuture this Fall for a discussion on #psychedelics and the future of #mentalhealth.
?? Just Announced for #BioFuture2024!? Join us in #NYC at Cure. from October 28-30, 2024, where industry pioneers, innovators, and visionaries will gather to shape the future of #healthcare. From #QuantumComputing and #AI to #Psychedelics and #TechBio, this year's BioFuture? will dive deep into the most pressing topics in the industry. ?? Featured Sessions:? ? ?? Quantum Computing and Biology: The Convergence Reshaping the Future of Human Health with Victoria Lipinska, PhD Quantum Engagement Lead at IBM Quantum.? ?? The Future of Psychedelics: Interventions for Mental Health with Virginia Amann, Founder of ENTENTE Network.? ?? Big Think Plenary: Tackling the Hard Questions: Policy, PBMs, The IRA – get ready for thought-provoking discussions. ??? Coming in 2024: Get ready for TechBio Panels that offer fresh perspectives and take advantage of one-on-one meetings and networking receptions with key investors and pharma executives. ?? Register now and join us: https://bit.ly/474dUs0? ?? See the full program here: https://bit.ly/4g4RlI1 #Biotech #Biopharma #LifeSciences #DigitalHealth #HealthcareInnovation #DrugDevelopment #Therapeutics #VC #VCFunding #Partnering #BiotechLeaders #Collaboration #DemyColton
-
Hear from CEO Virginia Amann about where communications can take the bioscience industry on the Vital Transformation Vital Health podcast ????
Strategic and Marketing Communications Leader. Science. Innovation. Founder/CEO/Shareholder ENTENTE Network of Companies
Thank you to Duane Schulthess Joseph Hammang, Ph.D. Gwen O'Laughlin and the entire Vital Transformation team for hosting me on the Vital Health Podcast, where I dish about what went wrong (and right!) in bioscience over the last several years and what the industry can do to position itself for a successful future. #VitalHealth #Podcast https://lnkd.in/gv-hPUDX
Transforming Health Communications: Insights from Virginia Amann
omny.fm
-
Katie Morris, PhD's top takeaways from C&EN Media Group's marketing communications summit ????
First up at #MarketingOnTheEdge this morning was Paul Avery, CEO of BioStrata. Great insights from Paul on AI's impact on #sciencemarketing and how science brands can win at content in the age of #artificialintelligence. We can't wait to share more from Paul on our blog in the coming weeks! https://lnkd.in/eFHdiJSZ
-
-
Great tips on messaging from our CEO and Founder.
Strategic and Marketing Communications Leader. Science. Innovation. Founder/CEO/Shareholder ENTENTE Network of Companies
Over the years my colleagues have joked that I'm "the wolf of communications" - in other words, a fixer. I fix bad plans, bad branding, bad strategic approaches, bad writing, and bad situations. Lately I'm alarmed by the amount of bad messaging I see, so I have a few tips. 1/ Don't rush. Messaging - good or bad - will become the foundation for every single thing you put out into the public domain - and ultimately how people understand what you do, who you are, and why it matters. Don't imagine message development is a simple or easy process. It takes time and effort to get it right. 2/ Be sure you are working with people who really understand your innovation and science, the market forces impacting your business, your competitive landscape, your strategy, and your personality. Give them time to get to know you. Make sure they're being thoughtful about it and can walk you through their thinking. 3/ Look for people who can help by using advanced tools and databases to assess these things. 4/ Be collaborative. Messaging done right reflects your leadership and authentic voice. Be present and open to the process. 5/ Be honest with the people helping you. About everything. The skeletons in the closet, the past criticisms, what keeps you up at night. But also what you are optimistic and excited about, where you hope things will move to, and what you think the impact could be. 6/ Don't be timid. Messaging should be ambitious, bold, differentiating and... long range. It's one of the most important investments you can make in the future success of your organization.